Tumour Models London Day Two
Thursday, 7th December 2017
09.40 | Discovering Resistance Mechanisms by Insertional Mutagenesis in Mice
Michael Rugaard Jensen has a Ph.D. degree in molecular and cellular biology combined with an extensive experience in genetically engineered mice and more than 13 years of leading Oncology Drug Discovery efforts. Michael has for the past 5 year lead the Drug Discovery Pharmacology team that is using a diverse set of innovative in vivo technologies to ensure delivery of novel treatments for cancer patients.